Brief: Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints In Fibromyalgia Study
30/04/2025 13:13
April 30 (Reuters) - Silo Pharma Inc SILO.O: SILO PHARMA’S SP-26 KETAMINE IMPLANT MEETS ALL ENDPOINTS IN FIBROMYALGIA STUDY SILO PHARMA INC - NO IMPLANT-RELATED ADVERSE EVENTS OBSERVED IN STUDY Source text: ID:nGNX2RH3GK Further company coverage: SILO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement